- AU$3.61m
- AU$2.73m
- AU$1.65m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.86 | ||
| Price to Tang. Book | 7.86 | ||
| Price to Free Cashflow | 20.17 | ||
| Price to Sales | 1.99 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -313.08% | ||
| Return on Equity | -121.67% | ||
| Operating Margin | -79.2% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.8 | 1.46 | 1.56 | 1.43 | 1.65 | n/a | n/a | 8.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19, and additional preclinical programs including Hepatitis B Virus (HBV). In addition, the Company has several early-stage programs designing drugs that target a class of virus protein known as viroporins, which have a key role in the virus life cycle of a range of viruses, such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. Its proprietary primary bacterial cell-based screening platform enables rapid screening of target viroporin proteins. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. The Company also has a portfolio of preclinical antiviral programs.
Directors
- Michael Hoy NEC
- Michelle Miller CEO
- Stephen Becker OTH
- Peter Nightingale SEC
- Stephen Locarnini DRC
- Susan Pond NID
- Robert Thomas NID (75)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 23rd, 1999
- Public Since
- January 24th, 2001
- No. of Shareholders
- 6,085
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 1,804,765,532
- Address
- Suite 3.3, 56 Delhi Road, NORTH RYDE, 2113
- Web
- https://www.biotron.com.au/
- Phone
- +61 298050488
- Auditors
- KPMG
Upcoming Events for BIT
Biotron Ltd Annual Shareholders Meeting
Similar to BIT
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Biotron share price?
As of Today at 19:37 UTC, shares in Biotron are trading at AU$0.00. This share price information is delayed by 15 minutes.
How has the Biotron share price performed this year?
Shares in Biotron last closed at AU$0.00 and the price had moved by -93.07% over the past 365 days. In terms of relative price strength the Biotron share price has underperformed the ASX All Ordinaries Index by -93.61% over the past year.
What are the analyst and broker recommendations for Biotron?
There is no consensus recommendation for this security.
Find out moreWhat is the Biotron dividend yield?
Biotron does not currently pay a dividend.
Does Biotron pay a dividend?
Biotron does not currently pay a dividend.
When does Biotron next pay dividends?
Biotron does not currently pay a dividend.
How do I buy Biotron shares?
To buy shares in Biotron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biotron?
As of the previous close price of AU$0.00, shares in Biotron had a market capitalisation of AU$3.61m.
Where are Biotron shares listed?
Here are the trading details for Biotron:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: BIT
What kind of share is Biotron?
Based on an overall assessment of its quality, value and momentum Biotron is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biotron share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Biotron share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotron. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -87.15%.
As of the last closing price of AU$0.00, shares in Biotron were trading -80.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biotron PE Ratio?
The Biotron PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biotron?
Biotron's management team is headed by:
- Michael Hoy - NEC
- Michelle Miller - CEO
- Stephen Becker - OTH
- Peter Nightingale - SEC
- Stephen Locarnini - DRC
- Susan Pond - NID
- Robert Thomas - NID